Abner Herrman & Brock Trim Intuitive Surgical Stake

by

Abner Herrman & Brock LLC, that ever-astute orchestra of investment acumen, recently decided to part ways with nearly 10,000 shares of [b]Intuitive Surgical[/b] (ISRG 1.39%), a transaction worth some $4.62 million, as the autumn leaves began their descent in September 2025. A modest pruning of the portfolio hedge, one might say, though not without its quiet drama.

The Plot Thickens

According to the 14th of October’s SEC filing-a document as eagerly anticipated in certain circles as the latest Agatha Christie-this reduction saw the firm’s holdings shrink to 21,861 shares, valued at $9.78 million. Picture, if you will, a gentleman reluctantly surrendering his last truffle at a dinner party: the sale represented 30% of their previous position, though one suspects the fund’s appetite remains intact. [em]The stock, you see, had been in something of a sulk[/em], down 10.6% year-on-year, sulking like a debutante excluded from the season’s premier ball.

Portfolio Peccadilloes

Now constituting 1.01% of AHB’s 13F assets, Intuitive Surgical shares rub shoulders with heavier hitters. The firm’s September ledger reads like a who’s who of Wall Street’s glitterati: [b]Nvidia[/b] ($77.59 million) glitters at the ballroom’s center, while [b]Microsoft[/b] and [b]IBM[/b] hold forth in the drawing room, each commanding 4.2% of AUM. Even [b]Netflix[/b] and [b]JPMorgan Chase[/b] manage cameos, the former streaming into portfolios at $40.30 million.

Company Snapshot: A Tale of Robotic Derring-Do

Metric Value
Price $435.73
Market Capitalization $155.49 billion
Revenue (TTM) $9.14 billion
Net Income (TTM) $2.61 billion

One might liken Intuitive Surgical to a dashing inventor in a Jules Verne novel-its da Vinci surgical system whirring away in operating theaters worldwide, while the Ion endoluminal system probes lung mysteries with the precision of Sherlock Holmes. Employing 15,600 souls, the firm marches onward, driven by innovation and the quiet thrill of expanding its robotic empire.

The Fool’s Gambit

Now, here’s where the plot twists like a Gilbert & Sullivan operetta. AHB’s sale preceded October’s earnings report, which arrived like a deus ex machina, silencing critics with 20% year-on-year procedure growth and a da Vinci 5 model so popular it might as well have its own fan club. Tariff worries? Medicaid jitters? Competitors nipping at their heels? Pah! All dispatched with the efficiency of a butler packing a picnic hamper.

Yet the firm’s trimming of [b]Stryker[/b] and [b]Abbott Laboratories[/b] stakes suggests a subtle shift-a waltz away from healthcare tech and into the arms of big tech’s glittering waltz. [b]Nvidia[/b], [b]Microsoft[/b], and even [b]Tesla[/b] received fresh invitations to the ball, their potential for growth as intoxicating as a vintage Château Margaux.

Glossary: A Primer for the Uninitiated

AUM: The grand total of investments a fund juggles without dropping a single coin.
13F: A quarterly SEC filing, required reading for those who find suspense in spreadsheets.
Da Vinci Surgical System: A robotic marvel, making surgeons look like conductors of a mechanical orchestra.
Installed Base: Not a group of disgruntled mechanics, but the number of products currently in use.
TTM: Twelve months of financial data, condensed like a well-aged port.

And thus, dear reader, we find ourselves at the intersection of caution and optimism-a place where portfolios are trimmed not for lack of faith, but to make room for new suitors. Intuitive Surgical, like a heroine in a drawing-room comedy, emerges from this chapter with her chin up and her robots whirring. 🎩🚀

Read More

2025-10-31 03:52